Single FGF-23 measurement and time-averaged plasma phosphate levels in hemodialysis patients

Clinical Journal of the American Society of Nephrology

Volumn 8, Issue 10, 2013, Pages 1764-1772

  Seiler, Sarah ^a   Lucisano, Gaetano ^a   Ege, Philipp ^a   Fell, Lisa H ^a   Rogacev, Kyrill S ^a   Lerner Gräber, Anne ^a   Klingele, Matthias ^a   Ziegler, Matthias ^b   Fliser, Danilo ^a   Heine, Gunnar H ^a  

^a SAARLAND UNIVERSITY   (Germany)

^b HUMBOLDT UNIVERSITY   (Germany)

Author keywords

[No Author keywords available]

Indexed keywords

ALKALINE PHOSPHATASE; ALUMINUM HYDROXIDE; CALCIFEDIOL; CALCIUM; CALCIUM ACETATE; CINACALCET; FIBROBLAST GROWTH FACTOR 23; LANTHANUM CARBONATE; MAGNESIUM CARBONATE; PARATHYROID HORMONE; PHOSPHATE; SEVELAMER; VITAMIN D;

AGED; ARTICLE; BONE DISEASE; CHRONIC KIDNEY FAILURE; CLINICAL ARTICLE; ENZYME LINKED IMMUNOSORBENT ASSAY; FEMALE; HEMODIALYSIS; HUMAN; MALE; PARATHYROIDECTOMY; PHOSPHATE BLOOD LEVEL;

AGED; CALCIUM; FEMALE; FIBROBLAST GROWTH FACTORS; HUMANS; KIDNEY FAILURE, CHRONIC; MALE; MIDDLE AGED; PARATHYROID HORMONE; PHOSPHATES; RENAL DIALYSIS;

EID: 84885201803     PISSN: 15559041     EISSN: 1555905X     Source Type: Journal    
DOI: 10.2215/CJN.13021212     Document Type: Article

References (34)

1. Ketteler M, Wolf M, Hahn K, Ritz E: Phosphate: A novel cardiovascular risk factor. Eur Heart J 34: 1099-1101, 2013
2. Block GA, Hulbert-Shearon TE, Levin NW, Port FK: Association of serum phosphorus and calcium x phosphate product with mortality risk in chronic hemodialysis patients: A national study. Am J Kidney Dis 31: 607-617, 1998
3. Block GA, Klassen PS, Lazarus JM, Ofsthun N, Lowrie EG, Chertow GM: Mineral metabolism, mortality, and morbidity in maintenance hemodialysis. J Am Soc Nephrol 15: 2208-2218, 2004
4. Tentori F, Blayney MJ, Albert JM, Gillespie BW, Kerr PG, Bommer J, Young EW, Akizawa T, Akiba T, Pisoni RL, Robinson BM, Port FK: Mortality risk for dialysis patients with different levels of serum calcium, phosphorus, and PTH: The Dialysis Outcomes and Practice Patterns Study (DOPPS). Am J Kidney Dis 52: 519-530, 2008
5. Wald R, Sarnak MJ, Tighiouart H, Cheung AK, Levey AS, Eknoyan G, Miskulin DC: Disordered mineral metabolism inhemodialysis patients: An analysis of cumulative effects in the Hemodialysis (HEMO) Study. Am J Kidney Dis 52: 531-540, 2008
6. Shroff R, Long DA, Shanahan C: Mechanistic insights into vascular calcification in CKD. J Am Soc Nephrol 24: 179-189, 2013
7. Kidney Disease: Improving Global Outcomes (KDIGO) CKD-MBD Work Group: KDIGO clinical practice guideline for the diagnosis, evaluation, prevention, and treatment of Chronic Kidney Disease-Mineral and Bone Disorder (CKD-MBD). Kidney Int Suppl 113: S1-S130, 2009
8. Ring T, Sanden AK, Hansen HH, Halkier P, Nielsen C, Fog L: Ultradian variation in serum phosphate concentration in patients on haemodialysis. Nephrol Dial Transplant 10: 59-63, 1995
9. Levitt H, Smith KG, Rosner MH: Variability in calcium, phosphorus, and parathyroid hormone in patients on hemodialysis. Hemodial Int 13: 518-525, 2009
10. Liu S, Tang W, Zhou J, Stubbs JR, Luo Q, Pi M, Quarles LD: Fibroblast growth factor 23 is a counter-regulatory phosphaturic hormone for vitamin D. J Am Soc Nephrol 17: 1305-1315, 2006
11. Kawata T, Imanishi Y, Kobayashi K, Miki T, Arnold A, Inaba M, Nishizawa Y: Parathyroid hormone regulates fibroblast growth factor-23 in a mouse model of primary hyperparathyroidism. J Am Soc Nephrol 18: 2683-2688, 2007
12. Baum M, Schiavi S, Dwarakanath V, Quigley R: Effect of fibroblast growth factor-23 on phosphate transport in proximal tubules. Kidney Int 68: 1148-1153, 2005
13. Seiler S, Heine GH, Fliser D: Clincial relevance of FGF-23 in chronic kidney disease. Kidney Int 114: S34-S42, 2009
14. Heine GH, Seiler S, Fliser D: FGF-23: The rise of a novel cardiovascular risk marker in CKD. Nephrol Dial Transplant 27: 3072-3081, 2012
15. Parker BD, Schurgers LJ, Brandenburg VM, Christenson RH, Vermeer C, Ketteler M, Shlipak MG, Whooley MA, Ix JH: The associations of fibroblast growth factor 23 and uncarboxylated matrix Gla protein with mortality in coronary artery disease: The Heart and Soul Study. Ann Intern Med 152: 640-648, 2010
16. Rogacev KS, Seiler S, Zawada AM, Reichart B, Herath E, Roth D, Ulrich C, Fliser D, Heine GH: CD14++CD16+ monocytes and cardiovascular outcome in patients with chronic kidney disease. Eur Heart J 32: 84-92, 2011
17. Rogacev KS, Cremers B, Zawada AM, Seiler S, Binder N, Ege P, Große-Dunker G, Heisel I, Hornof F, Jeken J, Rebling NM, Ulrich C, Scheller B, Bohm M, Fliser D, Heine GH: CD14++CD16+ monocytes independently predict cardiovascular events: A cohort study of 951 patients referred for elective coronary angiography. J Am Coll Cardiol 60: 1512-1520, 2012
18. Ketteler M, Petermann AT: Phosphate and FGF23 in early CKD: On how to tackle an invisible foe. Nephrol Dial Transplant 26: 2430-2432, 2011
19. Perry HM 3rd, Province MA, Droke DM, Kim GS, Shaheb S, Avioli LV: Diurnal variation of serum calcium and phosphorus in postmenopausal women. Calcif Tissue Int 38: 115-118, 1986
20. Ishida M, Seino Y, Yamaoka K, Tanaka Y, Satomura K, Kurose Y, Yabunchi H: The circadian rhythms of blood ionized calcium in humans. Scand J Clin Lab Invest Suppl 165: 83-86, 1983
21. Isakova T, Xie H, Barchi-Chung A, Vargas G, Sowden N, Houston J, Wahl P, Lundquist A, Epstein M, Smith K, Contreras G, Ortega L, Lenz O, Briones P, Egbert P, Ikizler TA, Jueppner H, Wolf M: Fibroblast growth factor 23 in patients undergoing peritoneal dialysis. Clin J Am Soc Nephrol 6: 2688-2695, 2011
22. Taylor EN, Rimm EB, Stampfer MJ, Curhan GC: Plasma fibroblast growth factor 23, parathyroid hormone, phosphorus, and risk of coronary heart disease. Am Heart J 161: 956-962, 2011
23. Semba RD, Fink JC, Sun K, Cappola AR, Dalal M, Crasto C, Ferrucci L, Fried LP: Serum fibroblast growth factor-23 and risk of incident chronic kidney disease in older community-dwelling women. Clin J Am Soc Nephrol 7: 85-91, 2012
24. Seiler S, Reichart B, Roth D, Seibert E, Fliser D, Heine GH: FGF23 and future cardiovascular events in patients with chronic kidney disease before initiation of dialysis treatment. Nephrol Dial Transplant 25: 3983-3989, 2010
25. Isakova T, Xie H, Yang W, Xie D, Anderson AH, Scialla J, Wahl P, Gutiérrez OM, Steigerwalt S, He J, Schwartz S, Lo J, Ojo A, Sondheimer J, Hsu CY, Lash J, Leonard M, Kusek JW, Feldman HI, Wolf M; Chronic Renal Insufficiency Cohort (CRIC) Study Group: Fibroblast growth factor 23 and risks of mortality and end-stage renal disease in patients with chronic kidney disease. JAMA 305: 2432-2439, 2011
26. Kendrick J, Cheung AK, Kaufman JS, Greene T, Roberts WL, Smits G, Chonchol M; HOST Investigators: FGF-23 associates with death, cardiovascular events, and initiation of chronic dialysis. J Am Soc Nephrol 22: 1913-1922, 2011
27. Gutiérrez OM, Mannstadt M, Isakova T, Rauh-Hain JA, Tamez H, Shah A, Smith K, Lee H, Thadhani R, Juppner H, Wolf M: Fibroblast growth factor 23 and mortality among patients undergoing hemodialysis. N Engl J Med 359: 584-592, 2008
28. Jean G, Terrat JC, Vanel T, Hurot JM, Lorriaux C, Mayor B, Chazot C: High levels of serum fibroblast growth factor (FGF)-23 are associated with increased mortality in long haemodialysis patients. Nephrol Dial Transplant 24: 2792-2796, 2009
29. American Diabetes Association: Standards of medical care in diabetes-2009. Diabetes Care 32[Suppl 1]: S13-S61, 2009
30. Hryszko T, Rydzewska-Rosolowska A, Brzosko S, Koc-Zorawska E, Mysliwiec M: Low molecular weight iron dextran increases fibroblast growth factor-23 concentration, together with parathyroid hormone decrease in hemodialyzed patients. Ther Apher Dial 16: 146-151, 2012
31. Munoz Mendoza J, Isakova T, Ricardo AC, Xie H, Navaneethan SD, Anderson AH, Bazzano LA, Xie D, Kretzler M, Nessel L, Hamm LL, Negrea L, Leonard MB, Raj D, Wolf M; Chronic Renal Insufficiency Cohort: Fibroblast growth factor 23 and inflammation in CKD. Clin J Am Soc Nephrol 7: 1155-1162, 2012
32. Seiler S, Cremers B, Rebling NM, Hornof F, Jeken J, Kersting S, Steimle C, Ege P, Fehrenz M, Rogacev KS, Scheller B, Bohm M, Fliser D, Heine GH: The phosphatonin fibroblast growth factor 23 links calcium-phosphate metabolism with left-ventricular dysfunction and atrial fibrillation. Eur Heart J 32: 2688-2696, 2011
33. Wolf M: Update on fibroblast growth factor 23 in chronic kidney disease. Kidney Int 82: 737-747, 2012
34. Fassbender WJ, Brandenburg V, Schmitz S, Sandig D, Simon SA, Windolf J, Stumpf UC: Evaluation of human fibroblast growth factor 23 (FGF-23) C-terminal and intact enzyme-linked immunosorbent-assays in end-stage renal disease patients. Clin Lab 55: 144-152, 2009